2018
DOI: 10.12659/aot.907167
|View full text |Cite
|
Sign up to set email alerts
|

Clinical Features, Treatment and Prognostic Factors of Post-Transplant Immunoglobulin A Nephropathy

Abstract: BackgroundInitially described as a relatively benign condition, recent studies report graft loss in up to 50% of the patients with post-transplant IgA nephropathy. There is no evidence for the best therapeutic approach, and prognostic factors remain to be elucidated.Material/MethodsSingle center retrospective analysis of patients >12 years old, with clinically relevant post-transplant IgA nephropathy (proteinuria ≥1.0 g/g and/or graft dysfunction) and ≥6 months follow-up after diagnosis (n=47).ResultsLiving do… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
6
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 10 publications
(7 citation statements)
references
References 34 publications
1
6
0
Order By: Relevance
“…The impact of posttransplant MN on allograft survival remains controversial [4]. In fact, in our study graft and patient survival were similar to those previously reported by our center [2022]. …”
Section: Discussionsupporting
confidence: 89%
“…The impact of posttransplant MN on allograft survival remains controversial [4]. In fact, in our study graft and patient survival were similar to those previously reported by our center [2022]. …”
Section: Discussionsupporting
confidence: 89%
“…[ 25 ] Data from a large tertiary care military hospital in North India have revealed an estimated graft survival at 5 years of 80.5%. [ 26 ] The available studies comparing the graft survival of posttransplant IgAN patients with overall survival show variable outcomes[ 10 11 12 13 14 18 27 28 29 30 31 32 33 34 35 36 ] as shown in Table 4 .…”
Section: Discussionmentioning
confidence: 99%
“…[ 7 ] For posttransplant IgAN, most studies showed that patients with clinical recurrence of IgAN have a lower long-term graft survival than patients without recurrence. [ 7 11 13 16 18 31 32 33 34 35 36 ] Local variations in patient demographics and medical practice can contribute to differences in renal outcomes in patients with IgAN in native kidney disease. [ 37 ] These local variations might be important in the posttransplant IgAN as well.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…The treatment of KT recipients with recurrent IgAN is still based on empirical strategies and remains the main area of uncertainty for transplant nephrologists. In addition, despite RAS blockade treatment, 30-50% of recipients with recurrent IgAN finally lose their renal allograft [5,10,11]. Moreover, methylprednisolone pulse therapy or increased doses of oral steroids in recurrent IgAN post-KT demonstrate the unfavorable outcomes [11] and enhanced steroid side effects, including metabolic disturbances, steroid-induced cataracts and overt immune suppression, in KT recipients.…”
Section: Introductionmentioning
confidence: 99%